共 50 条
von Willebrand factor propeptide: biology and clinical utility
被引:62
|作者:
Haberichter, Sandra L.
[1
,2
,3
]
机构:
[1] BloodCtr Wisconsin, Diagnost Labs, Milwaukee, WI 53201 USA
[2] BloodCtr Wisconsin, Blood Res Inst, Milwaukee, WI 53201 USA
[3] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA
来源:
基金:
美国国家卫生研究院;
关键词:
VONWILLEBRAND-FACTOR VWF;
WEIBEL-PALADE BODIES;
ANTIGEN-II;
DEFECTIVE MULTIMERIZATION;
ENDOTHELIAL DYSFUNCTION;
REGULATED SECRETION;
FACTOR SURVIVAL;
FACTOR STORAGE;
PLASMA-LEVELS;
FACTOR-VIII;
D O I:
10.1182/blood-2015-04-512731
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
von Willebrand factor (VWF) is a large multimeric glycoprotein that mediates the attachment of platelets to damaged endothelium and also serves as the carrier protein for coagulation factor VIII (FVIII), protecting it from proteolytic degradation. Quantitative or qualitative defects in VWF result in von Willebrand disease (VWD), a common inherited bleeding disorder. VWF is synthesized with a very large propeptide (VWFpp) that is critical for intracellular processing of VWF. VWFpp actively participates in the process of VWF multimerization and is essential for trafficking of VWF to the regulated storage pathway. Mutations identified within VWFpp in VWD patients are associated with altered VWF structure and function. The assay of plasma VWFpp has clinical utility in assessing acute and chronic vascular perturbation associated with diseases such as thrombotic thrombocytopenic purpura, sepsis, and diabetes among others. VWFpp assay also has clear utility in the diagnosis of VWD subtypes, particularly in discriminating true type 3 subjects from type 1C (reduced plasma survival of VWF), which is clinically important and has implications for therapeutic treatment.
引用
收藏
页码:1753 / 1761
页数:9
相关论文